Oncohematology
type: channel
description: Peer-rewieved medical journal for oncohematology
publisher: "PH "ABV-Press"", LLC
language: ru-RU
publication name: Oncohematology
issn: 1818-8346
copyright: Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
items: Efficacy of the nivolumab + AVD regimen in the treatment of newly diagnosed classical Hodgkin’s lymphoma: Leningrad Regional Clinical Hospital experience
items: Kidney damage in chronic lymphocytic leukemia
items: Molecular methods for assessing tumor genome instability in acute myeloid leukemia
items: Features of the subpopulation composition and functional activity of peripheral blood lymphocytes and monocytes in patients with primary autoimmune thrombocytopenia
items: Invasive fungal diseases in recipients of allogeneic hematopoietic stem cells: current state of the problem
items: Practice of inflammatory biomarkers for prediction of infectious complications after autologous hematopoietic stem cell transplantation
items: Molecular phenotype of diffuse large B-cell lymphoma as a basis for a personalized treatment approach of elderly patients
items: Experience with acalabrutinib as a component of molecularly adapted antitumor therapy according to the R-CHOP-X protocol in patients with newly diagnosed diffuse large B-cell lymphoma
items: Clinical and pharmacogenetics factors as therapeutic predictors in pediatric acute lymphoblastic leukemia
items: The experience of a multidisciplinary team in maintaining fertility in oncohematological patients
items: Adherence to treatment in patients with multiple myeloma and pain syndrome
items: Differential diagnostic search for hypereosinophilic syndrome
items: c-MAF protein expression in multiple myeloma
items: Current trends and future of gene-cell immunotherapy in the treatment of HIV infection
items: Characteristics of regional epidemiological indicators of chronic myeloproliferative neoplasms
items: Genetic features of indolent and advanced forms of systemic mastocytosis
items: Results of asciminib therapy as part of managed access program in patients with chronic myeloid leukemia with T315I mutation
items: The significance of miR-142 in tumor progression of diffuse large B-cell lymphoma
items: Modern possibilities for diagnosing and tumor clone monitoring, determined by multicolor flow cytometry, in Waldenstrom’s macroglobulinemia
items: https://oncohematology.abvpress.ru/ongm/article/view/1036

Efficacy of the nivolumab + AVD regimen in the treatment of newly diagnosed classical Hodgkin’s lymphoma: Leningrad Regional Clinical Hospital experience
type: item
description: Aim. To analyze the efficacy and safety of combining nivolumab with AVD chemotherapy (N-AVD) in patients with newly diagnosed classical Hodgkin’s lymphoma in real-world evidence studies. Materials and methods. The retrospective single-center study included 26 patients (14 men, 12 women) with advanced disease stages (IIB with unfavorable prognostic factors according to GHSG (German Hodgkin Study Group) or III–IV according to the Ann Arbor classification). Patients received therapy at the Leningrad Regional Clinical Hospital from March 2023 to February 2025. The N-AVD regimen included nivolumab at a dose of 3 mg / kg (maximum 240 mg), doxorubicin 25 mg / m2, vinblastine 6 mg / m2, and dacarbazine 375 mg / m2 on days 1 and 15 every 28 days. Patients with stage IIB were planned to receive 4 cycles of N-AVD, in case of stages III–IV – 6. Some patients received consolidating proton therapy – 6 (24 %) or 3D conformal radiation therapy – 6 (24 %). The primary endpoint of the study was progression-free survival, and secondary endpoints were the complete remission rate, safety, event-free survival, and overall survival. Results. The complete remission rate was 94 %. With a median follow-up of 11.9 months, 1‑year progression-free survival was 95.7 %, and overall survival – 100 %. The most common adverse events were grade 3–4 neutropenia (46.2 %) and febrile neutropenia (11.5 %). Immune-mediated complications represented by two cases of hypothyroidism and acute pericarditis in one patient. Conclusion. Preliminary results of our study demonstrate the high efficiency of the N-AVD regimen and emphasize the importance of monitoring immune-mediated complications. The advisability of consolidation radiotherapy in patients with complete remission on anti-PD1 monoclonal antibody therapy requires further study. Our study confirms the prospects of using the N-AVD regimen in patients with newly diagnosed classical Hodgkin’s lymphoma, but longer follow-up and a larger sample are needed for…
creator: M. A. Ulyanova
creator: V. I. Vorob’ev
creator: S. V. Semochkin
creator: Yu. N. Vinogradova
creator: V. V. Basmanova
creator: R. D. Bekoev
creator: M. I. Ganzin
creator: V. S. Grishko
creator: R. R. Sabitova
creator: Ts. B. Tsyrenzhabe
creator: O. S. Uspenskaya
creator: S. M. Alekseev
date: 2025-09-11
publication date: 2025-09-11
volume: 20

Kidney damage in chronic lymphocytic leukemia
type: item
description: Chronic lymphocytic leukemia is the most common type of leukemia in adults. Kidney damage can be diagnosed at the onset of the disease or during its progression, relapse. In most studies, kidney damage in this disease was verified by the results of biopsy. Studies of recent decades have identified a wide range of kidney lesions in chronic lymphocytic leukemia, including lymphoid infiltration of parenchyma, glomerular and tubular damage caused by a monoclonal protein (M-protein) produced by B cells, thrombotic microangiopathy, worsening of comorbid pathology, additional infection, paraneoplastic reactions, tumor lysis syndrome, and drug-induced toxic kidney injury with damage of glomeruli, tubules, or renal vessels. In this article, we consider various forms of kidney disease associated with chronic lymphocytic leukemia.
creator: V. V. Cherepanova
creator: A. D. Saydov
creator: Z. D. Mikhaylova
date: 2025-09-11
publication date: 2025-09-11
volume: 20

Molecular methods for assessing tumor genome instability in acute myeloid leukemia
type: item
description: Laboratory diagnostics of acute myeloid leukemia enables accurate risk stratification of patients into prognostic groups according to modern classifications and facilitates personalized treatment selection. However, relapses and refractory forms still occur within each prognostic group. Some cytogenetic and molecular aberrations cannot be detected using standard diagnostic methods. Modern advanced laboratory techniques may uncover the mechanisms of tumor refractoriness and identify novel targets for therapy, which could improve acute myeloid leukemia diagnostics and patient prognosis.
creator: D. K. Bessmertnyy
creator: Z. T. Fidarova
date: 2025-09-11
publication date: 2025-09-11
volume: 20

Features of the subpopulation composition and functional activity of peripheral blood lymphocytes and monocytes in patients with primary autoimmune thrombocytopenia
type: item
description: Background. Primary immune thrombocytopenia (ITP) is an immune-mediated disease characterized by platelet destruction and impaired thrombopoiesis with the development of varying severity hemorrhagic syndrome. The first line of therapy for ITP patients are glucocorticosteroids, which have limited efficacy and frequent complications. Factors of innate and adaptive immunity play a key role in ITP pathogenesis, the study of which is especially relevant for assessing the immunological reactivity of patients and substantiating new therapeutic approaches in real clinical practice. Aim. To evaluate the characteristics of the subpopulation composition and functional activity of peripheral blood lymphocytes and monocytes in ITP patients and to identify possible immunological prognostic criteria for the disease course and resistance to glucocorticosteroid therapy. Materials and methods. In 20 patients with newly diagnosed ITP and in 20 ITP patients with resistance to glucocorticosteroid therapy, the relative and absolute parameters of T-lymphocytes (CD3+), B-lymphocytes (CD19+), NK cells (CD3–CD16+CD56+), T-helper cells (CD3+CD4+), T-cytotoxic (CD3+CD8+) and NKT (CD3+CD16+CD56+) subpopulations of peripheral blood lymphocytes, as well as the expression of HLA-DR on lymphocytes and monocytes, CD25 on CD4+ T-lymphocytes and CD40 on B -lymphocytes were analyzed using flow cytometry. Thirty healthy individuals were examined as a control group. Results. In patients with newly diagnosed ITP, a sharp decrease in the absolute number of B cells and T-helper lymphocytes in peripheral blood was observed, and pronounced activation of T-lymphocytes by HLA-DR expression and B-lymphocytes by costimulatory molecule CD40 expression was noted. In patients with glucocorticosteroids resistance, a significant decrease in the absolute number of peripheral blood T-helper lymphocytes, an increase in the content of activated CD3+HLA-DR+ lymphocytes were also detected, but the level of CD40+ B-lymphocyt…
creator: Yu. Yu. Chuksina
creator: S. G. Zakharov
creator: T. A. Mitina
date: 2025-09-11
publication date: 2025-09-11
volume: 20

Invasive fungal diseases in recipients of allogeneic hematopoietic stem cells: current state of the problem
type: item
description: Allogeneic hematopoietic stem cell transplantation is a standard treatment option for a variety of hematological disorders. In recent years, there has been observed an increase in transplantation activity worldwide as well as in use of alternative donors. Despite introduction of antifungal prophylaxis, recipients of allogeneic hematopoietic stem cells still have a high risk of invasive fungal disease. This review represents risk factors, frequency and structure of invasive fungal disease in this category of patients.
creator: D. A. Mironova
creator: L. A. Kuzmina
creator: G. A. Klyasova
date: 2025-09-11
publication date: 2025-09-11
volume: 20

Practice of inflammatory biomarkers for prediction of infectious complications after autologous hematopoietic stem cell transplantation
type: item
description: Background. High-dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (auto-HSCT) is a treatment option for hematological diseases, and can lead to severe neutropenia and an increased risk of infectious complications. The term “febrile neutropenia” combines all infectious complications, and fever may be the only sign of infection in this group of patients. Due to this, there is a need for additional diagnostic methods in clinical practice that can predict and diagnose infectious complications in patients after HDCT / auto-HSCT. Aim. To evaluate the prognostic significance of inflammatory biomarkers (C-reactive protein, procalcitonin and presepsin) in the early detection of infectious complications, as well as the capabilities of these biomarkers in the diagnosis of bacteremia in patients with lymphomas and plasma cell neoplasms after HDCT / auto-HSCT. Materials and methods. This prospective study included 139 patients with lymphomas and plasma cell neoplasms after HDCT / auto-HSCT. Infectious complications developed in the early post-transplant period in 99 (71.2 %) patients; 40 patients had no infectious complications, they formed the control group. The dynamics of C-reactive protein, procalcitonin and presepsin on day 1, 3 and 7 after stem cell infusion were assessed. Results. The median time of fever onset was 5 (1–10) days after transplantation. On day 3, significant differences were observed between the group of infectious complications and the control group in all biomarkers: C-reactive protein, procalcitonin and presepsin were significantly higher in the group of patients with infectious complications. On day 3, procalcitonin demonstrated the highest specificity for infection: with values >0.11 ng / mL, the probability of infectious complications increased by 9 times, and the specificity of the test reached 88.9 %. In 77 patients with febrile neutropenia, microbiological cultures were negative; in 21 patients – bacteremia wa…
creator: Yu. N. Dubinina
creator: V. O. Sarzhevskiy
creator: V. Ya. Melnichenko
creator: N. E. Mochkin
date: 2025-09-11
publication date: 2025-09-11
volume: 20

Molecular phenotype of diffuse large B-cell lymphoma as a basis for a personalized treatment approach of elderly patients
type: item
description: Background. The use of molecular genetic profiling in clinical practice and the registration of immunotargeted agents have undoubtedly led to the development of a personalized approach in oncohematology, with diffuse large B-cell lymphoma (DLBCL) being no exception. Elderly patients represent a complex group of patients with DLBCL, which leads to difficulties in treatment due to their comorbidity. Aim. To evaluate the efficacy, tolerability and safety of an individualized approach based on the mutational landscape in elderly patients with newly diagnosed DLBCL. Materials and methods. The clinical study included 10 elderly patients with newly diagnosed DLBCL. The median age was 68 (65–78) years. Eight patients were classified as being at high risk of early progression according to the international prognostic index. The frequency of genotypes in the considered cohort of elderly patients: MCD – 1 (10 %), N1 – 3 (30 %), BN2 – 1 (10 %), EZB – 2 (20 %), NOS – 3 (30 %). Results. Overall and complete metabolic response rates were 100 %. Clinically significant hematological toxicity depending on the number of cycles (n = 60): grade III–IV neutropenia in 5 cycles, grade III–IV thrombocytopenia in 2, grade III–IV anemia in 3. Non-hematological toxicity did not exceed grades I–II. Conclusion. High efficacy and low toxicity profile of a personalized approach in elderly patients with newly diagnosed DLBCL were demonstrated. The obtained preliminary results indicate the possibility of continuing the developed clinical study of elderly patients with DLBCL.
creator: M. A. Mingalimov
creator: E. A. Baryakh
creator: A. V. Misyurin
creator: L. A. Kesaeva
creator: A. S. Mkrtchyan
creator: E. N. Misyurina
creator: M. A. Donskoy
creator: T. N. Tolstykh
creator: M. S. Orlova
creator: T. S. Chudnova
creator: D. D. Ivanova
creator: O. L. Kochneva
creator: E. N. Zotina
creator: A. B. Makeshova
creator: S. S. Andreev
creator: D. V. Lebedev
creator: K. V. Yatskov
creator: I. V. Samsonova
creator: M. A. Lysenko
date: 2025-09-11
publication date: 2025-09-11
volume: 20

Experience with acalabrutinib as a component of molecularly adapted antitumor therapy according to the R-CHOP-X protocol in patients with newly diagnosed diffuse large B-cell lymphoma
type: item
description: Background. Despite tremendous progress in understanding tumor biology, the R-CHOP protocol remains the standard of care for diffuse large B-cell lymphoma (DLBCL). To date, six genetic variants of DLBCL have been identified, the most unfavorable of which when using standard therapy are N1, MCD and BN2, which dictates the need to optimize the treatment of these DLBCL subtypes. Aim. To evaluate the efficacy and toxicity of Acala-R-CHOP regimen in induction therapy in patients with newly diagnosed DLBCL. Materials and methods. The study included 15 patients who received Acala-R-CHOP program as part of the first-line therapy. This antitumor regimen was used for verified genotypes N1, MCD and BN2. The median age was 64 (38–78) years. The incidence of genetic variants in the considered cohort of patients: MCD – 13 % (n = 2), N1 – 74 % (n = 11), BN2 – 13 % (n = 2). Results. Fifteen patients completed the therapy. The overall and complete metabolic response rates were 100 %. Toxicity was moderate, quite manageable and manifested mainly as myelosuppression. Conclusion. The efficacy of Acala-R-CHOP therapy in patients with MCD, N1, and BN2 DLBCL genotypes is high with a low toxicity profile. However, longer follow-up periods are needed to assess the long-term results in this unfavorable group of patients.
creator: M. A. Mingalimov
creator: E. A. Baryak
creator: A. V. Misyurin
creator: L. A. Kesaeva
creator: A. S. Mkrtchyan
creator: E. N. Misyurina
creator: M. A. Donskoy
creator: T. N. Tolstykh
creator: M. S. Orlova
creator: T. S. Chudnova
creator: D. D. Ivanova
creator: O. L. Kochneva
creator: E. N. Zotina
creator: A. B. Makeshova
creator: S. S. Andreev
creator: K. V. Yatskov
creator: I. V. Samsonova
creator: M. A. Lysenko
date: 2025-09-11
publication date: 2025-09-11
volume: 20

Clinical and pharmacogenetics factors as therapeutic predictors in pediatric acute lymphoblastic leukemia
type: item
description: Background. Current protocols for pediatric acute lymphoblastic leukemia (ALL) are multicomponent, risk-adapted regimens in which high-dose (1–5 g / m2) methotrexate (MTX) is central. This drug has led to high long-term survival rates in children with ALL. Predicting the efficacy of the treatment given to further increase survival with minimization of toxic complications determines the relevance of pharmacogenetic studies to identify predictive biomarkers, implementing the personalized approach, which is essential for the development of modern practical medicine. Aim. To identify predictors of ALL therapy outcomes using pharmacogenetic biomarkers and clinical data. Materials and methods. A prospective analysis of pediatric ALL treatment outcomes was performed in a single-center observational (cohort) study. The analysis included 124 ALL patients who were treated according to the modern BFM (Berlin–Frankfurt–Munster) protocols with high-dose MTX. Treatment outcomes were compared with genetic polymorphisms of the ABCB1 gene, which is responsible for drug clearance (including MTX). Real-time polymerase chain reaction was used to study ABCB1 gene polymorphisms in peripheral blood. Statistical analysis of the influence of pharmacogenetic biomarkers was performed using SPSS Statistics 26.0 program (USA). To construct prognostic models, we used the method of logistic function construction by binary logistic regression with stepwise selection of factors and, if necessary, additional construction of ROC-curves with subsequent ROC-analysis. Differences were considered significant at p <0.05; at p ≥0.05, differences were considered unlikely and not statistically significant. Results. According to the conducted complex analysis of high-dose MTX therapy efficacy and safety, 3 reliable (p <0.001) prognostic models with high sensitivity, specificity, and efficiency (>70 %) were developed, demonstrating interrelations of clinical and genetic factors influencing adverse outcomes of …
creator: O. D. Gurieva
creator: T. T. Valiev
creator: M. I. Savelyeva
creator: S. R. Varfolomeeva
date: 2025-09-11
publication date: 2025-09-11
volume: 20

The experience of a multidisciplinary team in maintaining fertility in oncohematological patients
type: item
description: Background. Over the past few decades, the advancements in antitumor therapy, early diagnosis, and the development of stem cell transplantation techniques have led to a notable increase in the survival rates of oncohematological patients. Although effective chemotherapy has been shown to prolong lifespan, it can also contribute to toxic effects on gland function, which in women can result in impaired fertility and hormonal disorders related to sex hormone production. In order to mitigate or prevent the irreversible complications of antitumor therapy-induced gonadotoxicity, effective and comprehensive strategies that integrate a variety of options for preserving and restoring fertility should be implemented prior to, during, and following the chemotherapy or radiotherapy. Aim. To test in clinical practice the principles of creating a management plan for oncohematological patients of reproductive age prior to starting special treatment. Materials and methods. The study included 34 female patients of reproductive age with morphologically confirmed hematological diseases who underwent examination, treatment, and follow-up observation at the State Budgetary Healthcare Institution, City Clinical Hospital No. 52 of the Moscow Healthcare Department. All patients were referred for consultation with an obstetrician-gynecologist to evaluate their hormonal status and reproductive potential. Additionally, a multidisciplinary team, including a reproductive health specialist from REMEDI Institute of Reproductive Medicine LLC, assessed ovarian reserve and selected appropriate fertility preservation technique. A comprehensive review and discussion of all clinical cases was conducted within the framework of a multidisciplinary team, leading to a determination of the feasibility of fertility preservation. Results. The material for fertility preservation was collected in 82 % of the patients. Hodgkin’s lymphoma was the most common malignancy (76 %). The methods employed for material co…
creator: A. Yu. Kishkina
creator: N. A. Shevchenko
creator: E. S. Mladova
creator: О. V. Polikarpova
creator: I. M. Grashchenko
creator: V. V. Didenko
creator: Yu. К. Brichkalevich
creator: A. A. Povarova
creator: E. A. Baryakh
creator: D. D. Ivanova
creator: S. A. Parts
creator: V. N. Galkin
creator: M. A. Lysenko
creator: V. M. Grabovsky
date: 2025-09-11
publication date: 2025-09-11
volume: 20

Adherence to treatment in patients with multiple myeloma and pain syndrome
type: item
description: Background. Treatment adherence is one of the key factors influencing the therapy outcome in patients with multiple myeloma complicated by pain syndrome. Aim. To clarify the treatment adherence features in patients with multiple myeloma. Materials and methods. The data of 61 patients with pain syndrome associated with bortezomib-induced polyneuropathy and oral mucositis were studied. Men – 17 (27.9 %), women – 44 (72.1 %). Median age – 52 (31–67) years. Assessment of pain syndrome and psychometric parameters of patients was performed in hospital before autologous hematopoietic stem cell transplantation (1st point), on the 8th (2nd point) and 100th (3rd point) days after transplantation. Validated algometric and psychometric methods were used. Results. At each study point, patients with high adherence were grouped into 1st group, and patients with low adherence were grouped into 2nd group. At 1st point, statistically significant differences were noted between the groups in such indicators as quality of life / satisfaction and the degree of polyneuropathy. At the 2nd point, significant differences were found in the types of patient’s attitude toward illness: in the 1st group, adaptive types (harmonious, ergopathic) predominated, in the 2nd – maladaptive ones (anxious, neurasthenic, and sensitive). At 3rd point, a statistically significant difference was noted between the groups in the severity of mental disorders symptoms, the presence of which may be associated with decreased adherence to treatment, as well as the presence exclusively in the group with a low treatment adherence a maladaptive (egocentric) type of attitude toward illness. Conclusion. Adherence to treatment in patients with multiple myeloma complicated by pain syndrome is a complex problem that requires a multidisciplinary team of specialists, which should include hematologists, algologists, and mental health specialists (psychiatrists, medical psychologists).
creator: D. E. Vybornykh
creator: Z. E. Irugova
creator: L. V. Esina
creator: S. Yu. Fedorova
creator: M. V. Solov’ev
creator: M. V. Solov’eva
creator: L. P. Mendeleeva
date: 2025-09-11
publication date: 2025-09-11
volume: 20

Differential diagnostic search for hypereosinophilic syndrome
type: item
description: Idiopathic hypereosinophilic syndrome is characterized by a persistent increase in serum eosinophil counts >1.5 × 109 / L for 4 weeks and the absence of any clinical, laboratory and instrumental data suggesting the etiology of this phenomenon. It is not always possible to confirm the reactive nature of eosinophilia or identify clonal disease. The article presents a clinical case of differential diagnostic search for the cause of hypereosinophilia in a patient.
creator: A. S. Buzuk
creator: E. V. Chernova
creator: A. V. Koloskov
creator: V. N. Marchenko
date: 2025-09-11
publication date: 2025-09-11
volume: 20

c-MAF protein expression in multiple myeloma
type: item
description: Background. The c-MAF oncogene, located in the 16q23.2 region, encodes the protein of the same name, a transcription factor whose role continues to be studied. Given the activating effect of the c-MAF transcription factor in enhancing the interaction between the tumor cell and the bone marrow stroma, we hypothesized that c-MAF protein expression would be more frequently detected in multiple myeloma (MM) patients without plasmacytomas. Aim. To analyze the c-MAF protein expression pattern in bone marrow trephine biopsy specimens of patients with newly diagnosed MM with and without plasmacytomas. Materials and methods. The retrospective single-center study included 31 patients (7 men and 24 women) with newly diagnosed MM aged 29 to 78 years (median – 55 years). The first cohort of patients included 12 patients with t(14;16), the second cohort – 19 patients without this translocation. In 21 patients, plasmacytomas were not detected at the disease onset, in 10 patients, bone or extramedullary plasmacytomas were detected. Low-dose body computed tomography was used to detect bone lesions. The diagnosis was established in accordance with the International Myeloma Working Group 2014 criteria. Positive immunomagnetic selection of CD138+ bone marrow cells was performed using a monoclonal antibody to CD138 (Miltenyi Biotec, Germany) according to the manufacturer’s protocol. Fluorescent hybridization in situ of CD138+ cells was performed using DNA probes to detect translocations 14q32 / IgH, 8q24 / MYC, deletions 17p13 / TP53, 13q14, 1p32, amplification of 1q21 (amp1q21) and multiple trisomies (MetaSystems, Germany). High-risk cytogenetic aberrations included t(14;16), t(4;14), del17p13, amp1q21. Immunohistochemical examination of bone marrow trephine biopsy specimens using c-MAF antibody was performed in all patients. A heterogeneous or monomorphic nuclear reaction in more than 10 % of the tumor plasma cells was considered as positive c-MAF protein expression. Results. Cytogene…
creator: M. V. Solov’eva
creator: M. V. Solov’ev
creator: M. V. Melnikova
creator: A. M. Kovrigina
creator: T. N. Obukhova
creator: L. P. Mendeleeva
date: 2025-09-11
publication date: 2025-09-11
volume: 20

Current trends and future of gene-cell immunotherapy in the treatment of HIV infection
type: item
description: Despite significant advancements in antiretroviral therapy, HIV viral reservoirs continue to persist even in patients receiving combination therapy. In recent years, promising results have emerged in HIV treatment, including two cases of functional cure known as the “Berlin patient” and the “London patient”, both of whom received allogeneic hematopoietic stem cell transplants from donors with the CCR5Δ32 mutation. These cases underscore the importance of genetically modified stem cells in achieving resistance to HIV. The development of genome editing methods, such as CRISPR/Cas9, opens new horizons for creating targeted therapies aimed at eliminating the virus from infected cells. Research also shows promise in the application of cell immunotherapy, including CAR T-cells and NK cells, which may enhance control over HIV due to their ability to recognize and destroy infected cells. In light of these achievements, research in gene therapy targeting co-receptors, as well as new approaches such as virus activation and elimination methods, represents critical steps toward achieving a functional cure for HIV. This review discusses progress in genetic manipulation, immunotherapy, and the adaptation of conditioning regimens to develop effective treatment strategies for a broad range of HIV patients.
creator: A. P. Faenko
creator: G. A. Dudina
creator: Ch. K. Mabudzade
creator: A. A. Ogannisyan
date: 2025-05-22
publication date: 2025-05-22
volume: 20

Characteristics of regional epidemiological indicators of chronic myeloproliferative neoplasms
type: item
description: Background. Information on the epidemiological picture of chronic myeloid leukemia (CML) and, especially, Ph– chronic myeloproliferative neoplasm (MPN) in Russia is very scarce, each regional population study is important for obtaining information on the diseases in general. Aim. To analyze the regional epidemiological parameters of the most common MPN over a long period of time (2012–2023). Materials and methods. Clinical and epidemiological, population, retrospective-prospective, observational study of CML and classical Ph– MPN (polycythemia vera, essential thrombocythemia, primary myelofibrosis) was conducted at the Moscow City Hematology Center, Botkin Hospital. The observation period was from January 1, 2012 to December 31, 2023. The research database included data from the medical records of regional patients (Moscow). Results. At the time of analysis, the database contained 2191 patients with CML and 5831 with Ph– MPN observed since 2000. In both cohorts, women prevailed with a ratio of 1:1.1 for CML and 1:1.6 for Ph– MPN. The median age of patients in the overall cohort since 2000 at diagnosis of CML was 55 years (men – 52, women – 57), and of Ph– MPN – 64 years (men – 62, women – 64). During the study period, an increase in the median age and in the proportion of diagnosed CML patients aged 65 years and older were noted, the same was not observed in Ph– MPN. However, an increase in the median age and the proportion of elderly patients was revealed in both general cohorts of CML and Ph– MPN. The registered prevalence of CML and Ph– MPN over a 12-year period increased by 90 % (from 6.0 to 11.4 cases per 100,000 population) and 93 % (from 15.28 to 29.46 cases per 100,000 population), respectively. The high reliability of linear trends indicates a uniform increase in the prevalence of CML and Ph– MPN. The registered annual incidence rate of CML increased over 12 years from 0.74 to 1.13 cases per 100,000 population, and Ph– MPN – from 2.05 to 2.84. An increasing…
creator: O. Yu. Vinogradova
creator: A. L. Neverova
creator: M. V. Chernikov
creator: V. P. Kosenkova
creator: M. M. Pankrashkina
creator: D. I. Shikhbabaeva
creator: A. R. Vekua
creator: V. V. Ptushkin
date: 2025-05-22
publication date: 2025-05-22
volume: 20

Genetic features of indolent and advanced forms of systemic mastocytosis
type: item
description: Background. Mastocytosis is a group of diseases characterized by tumor proliferation of mast cells and their accumulation in organs and tissues, including skin, hematopoietic organs (bone marrow, spleen, lymph nodes), and the gastrointestinal tract, which is clinically manifested by symptoms of mast cell activation and organ infiltration in the form of hepatosplenomegaly, portal hypertension, ascites, and cytopenia. Of the greatest scientific and clinical interest is systemic mastocytosis (SM), where indolent (indolent SM, smoldering SM, SM with isolated bone marrow involvement) and advanced forms (aggressive SM, SM with associated hematological neoplasm and mast cell leukemia) are distinguished. The SM clinical course is extremely heterogeneous and diverse. Patients differ significantly from each other both in clinical manifestations and in the aggressiveness of the disease. Currently, there are no clear pathogenetic explanations for such a variety of clinical manifestations. More than 80 % of SM patients have the KITD816V mutation, and more than 50 other mutations in the KIT gene have been described. Additional mutations not associated with the KIT gene are being identified, which likely determine the SM clinical diversity. One of the directions that may help to understand the SM heterogeneity is an extended study of SM genetic characteristics using next-generation sequencing (NGS). Aim. To study the genetic features and differences between indolent and advanced SM forms. Materials and methods. The data of 27 SM patients (11 (41 %) men and 16 (59 %) women), observed at the Moscow City Hematology Center of the Botkin’s Hospital, were analyzed. The patients were divided into 2 groups: group 1 – patients with advanced SM variants, group 2 – patients with indolent SM variants. NGS was performed in all patients using the Illumina Myeloid Panel, which includes 40 genes. Results. As a result of the NGS study of 27 patients, mutations of unfavorable clinical significance …
creator: D. I. Shikhbabaeva
creator: O. Yu. Vinogradova
creator: Yu. N. Kobzev
creator: A. L. Neverova
creator: S. G. Malakho
creator: M. A. Molitvina
creator: M. M. Pankrashkina
creator: M. V. Chernikov
creator: V. V. Ptushkin
date: 2025-05-22
publication date: 2025-05-22
volume: 20

Results of asciminib therapy as part of managed access program in patients with chronic myeloid leukemia with T315I mutation
type: item
description: Background. The most common mechanism of resistance to tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML) is point mutations in the BCR::ABL1 gene. Of particular importance is the T315I mutation, which causes insensitivity of leukemia cells to all ATp-competitive TKIs: imatinib and 2nd generation TKIs. Asciminib is the first drug of the STAMp inhibitor class that specifically interacts with the myristoyl-binding active site of the bCR::AbL1 molecule. In a phase I clinical trial, asciminib at a dose of 200 mg twice daily showed efficacy in the treatment of chronic phase (Cp) CML patients with T315I mutation. There are no data on the efficacy of asciminib therapy in patients with T315I mutation and additional chromosomal abnormalities (ACA) or advanced disease. The Russian part of the managed access program (MAp) has accumulated its own experience of using asciminib in CML patients with T315I mutation, including those with ACA and history of progression to the acceleration phase / blast crisis. Aim. To analyze the 3-year results of asciminib therapy as part of MAp in CML patients with T315I mutation. Materials and methods. In the MAp program to asciminib between October 2019 and January 2022 were included 26 CML patients with T315I mutation who were ineffective or intolerant to ATp-competitive TKIs therapy. Asciminib was administered at a dose of 200 mg twice daily. The efficacy and tolerability of asciminib therapy were assessed in accordance with national clinical guidelines and the 2020 European LeukemiaNet guidelines. At the time of asciminib therapy initiation, 19 (73 %) patients had Cp. four (15 %) patients had a history of acceleration phase (n = 3) and blast crisis (n = 1). four (15 %) patients had ACA immediately before the start of asciminib therapy, including a patient with a history of blast crisis. To analyze the asciminib therapy results, patients with a history of progression and / or ACA were combined into one group…
creator: A. N. Petrova
creator: E. G. Lomaia
creator: E. V. Morozova
creator: O. A. Shukhov
creator: E. Yu. Chelysheva
creator: Yu. Yu. Vlasova
creator: E. A. Kuzmina
creator: O. V. Kulemina
creator: I. S. Nemchenko
creator: A. V. Bykova
creator: A. B. Sudarikov
creator: A. V. Kokhno
creator: A. G. Turkina
date: 2025-05-22
publication date: 2025-05-22
volume: 20

The significance of miR-142 in tumor progression of diffuse large B-cell lymphoma
type: item
description: In recent years, microRNAs have attracted the attention of researchers as potential markers for diagnosis, classification, prognosis of tumor progression and sensitivity to treatment, as well as their use as targets for therapy. The purpose of the review is to summarize data on the miR-142 role in the tumor progression of one of the most common lymphoproliferative diseases – diffuse large B-cell lymphoma. MicroRNA miR-142 has a broad spectrum of tumor-suppressor functions by targeting a number of important protooncogenes, the loss of control over which contributes to enhanced proliferation, blocking apoptosis, activating B-lymphocyte survival signaling pathways, metabolic reprogramming, creating an immunosuppressive microenvironment and tumor evasion of immune surveillance, as well as dissemination of malignant cells. Information on the nomenclature and mechanisms of miR-142 formation, the participation of miR-142 in hematopoiesis are provided, the pathogenetic role and relationship between the miR-142 expression profile and diffuse large B-cell lymphoma are analyzed, and miR-142 molecular genetic abnormalities in this disease are discussed.
creator: E. N. Voropaeva
creator: O. B. Seregina
creator: M. S. Voytko
creator: T. N. Babaeva
creator: N. V. Skvortsova
creator: V. N. Maksimov
creator: T. I. Pospelova
date: 2025-05-22
publication date: 2025-05-22
volume: 20

Modern possibilities for diagnosing and tumor clone monitoring, determined by multicolor flow cytometry, in Waldenstrom’s macroglobulinemia
type: item
description: Waldenstrom’s macroglobulinemia (WM) is a subtype of lymphoplasmacytic lymphoma that combines lymphoplasmacytic lymphoma substrate in the bone marrow and monoclonal immunoglobulin M secretion in the blood. WM diagnosis is a complex process, which is due to both the heterogeneity of tumor populations and similarity to other B-cell lymphomas. The WM tumor cell clone has unique immunophenotypic characteristics and is represented by two aberrant populations from one tumor clone: clonal B-lymphocytes and plasma cells. Detection and characterization of these two aberrant populations seems possible only using multicolor flow cytometry. Bone marrow cell immunophenotyping by flow cytometry establishes the tumor cell immunophenotype, which plays a key role in the differential diagnosis of WM from other types of small cell lymphomas, as well as when other methods are uninformative. To assess the depth of therapy response, instrumental and laboratory methods are used, including positron emission tomography combined with computed tomography to monitor the size and spread of the tumor mass, immunochemical testing to measure the monoclonal immunoglobulin M secretion, molecular bone marrow research for the presence of MYD88 gene mutations, as well as bone marrow cell immunophenotyping by multicolor flow cytometry. Currently, it is especially important to study the dynamics of minimal residual disease in WM using the capabilities of multicolor flow cytometry.
creator: A. B. Loginova
creator: I. V. Galtseva
creator: A. E. Grachev
creator: K. A. Nikiforova
creator: N. M. Kapranov
creator: Yu. A. Tsoy
creator: E. E. Zvonkov
date: 2025-05-22
publication date: 2025-05-22
volume: 20

https://oncohematology.abvpress.ru/ongm/article/view/1036
type: item
title: Invasive aspergillosis in patients with acute myeloid leukemia: difficulties in choosing first-line therapy in real clinical practice and pharmacoeconomic analysis of the feasibility of using new antifungal drugs
description: The article discusses the epidemiology and difficulties of diagnosing invasive aspergillosis in patients with acute myeloid leukemia, the role of pharmacokinetic and pharmacogenetic studies in choosing the optimal treatment regimen, and an attempt at pharmacoeconomic analysis to create an optimal treatment strategy for this complication.
creator: Yu. S. Osipov
creator: A. A. Antonov
creator: V. V. Ivanov
creator: G. N. Salogub
date: 2025-05-22
publication date: 2025-05-22
volume: 20